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A B S T R A C T
Quality of life (QoL) is an important outcome in assessment of breast cancer treatment. Data comparing QoL after dif-
ferent adjuvant treatments and QoL data on long-term survivors are modest. The aim of this study was to compare QoL
scores of patients receiving adjuvant treatment with long-term breast cancer survivors, and to correlate QoL scores with
clinical data. Sixty patients were recruited for the study: 20 during adjuvant radiotherapy, 20 during adjuvant chemo-
therapy, and 20 long-term breast cancer survivors. QoL was assessed using the self-administered EORTC core question-
naire QLQ-C30 and breast cancer-specific module QLQ-BR23. QoL scores between groups were compared using
Kruskal-Wallis test and effects of clinical factors on QoL domains were tested using multiple regression analysis. No dif-
ferences between three groups were observed in terms of all QoL scores. As measured by QLQ-C30, least affected QoL
scales were cognitive functioning, social functioning, and physical functioning in all three patients group, while insom-
nia and pain scales were the most detrimentally affected. Among the groups, the highest scores of global health status
and other functional scales were in adjuvant chemotherapy group. Measured by QLQ-BR23, body image scale was most
affected, while sexual functioning scale was minimally affected, in all three groups. Multiple regression analysis has
shown that the patient age were the only statistically significant predictor for global health status scale, and constipation
scale. Our results demonstrated similar and favorable QoL in all three groups of patients and provided basic informa-
tion on QoL in Croatian breast cancer patients.
Key words: breast cancer, quality of life, adjuvant chemotherapy, adjuvant radiotherapy, long-term survivors, ques-
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Introduction
Breast cancer is the most prevalent cancer in women
worldwide. There is a constant rising trend in new breast
cancer cases in the West Europe and United States, while
mortality trends are mostly decreasing. However, in Cro-
atia, both incidence and mortality are still rising, with al-
most 2500 women diagnosed with breast cancer and
more than 950 died in 20081.
The current mainstay of treatment for localised dis-
ease is breast conserving surgery (BCS) followed by
adjuvant radiotherapy which is equivalent to mastec-
tomy in terms of local control and survival2,3. Mastec-
tomy is reserved for more advanced cases and patient
preference, especially when combined with breast recon-
struction. Breast cancer patients receive adjuvant che-
motherapy and/or radiotherapy based on individual risk
assessment of disease recurrence4. Therefore, the multi-
ple modalities of treatment span surgery, chemotherapy,
radiation therapy, and endocrine therapy, with use of
each modality guided by pathological and clinical disease
characteristics.
Quality of life (QoL) can be defined as a complex, mul-
tifaceted phenomenon that reflects the physical, mental
and social well-being of the individual5. Various treat-
ment interventions and their side effects influence QoL.
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Surgery and patient’s awareness of being affected by ma-
lignant disease affect QoL extensively, besides the influ-
ence of adjuvant treatment6–8. Furthermore, the great
majority of breast cancer patients are postmenopausal
women with number of comorbidities that impact QoL. A
degree of QoL impairment is also present in long term
breast cancer survivors9.
Improvement of survival rates by earlier detection
and improved treatment makes QoL an increasingly rele-
vant endpoint to assess treatment outcomes10–13. Specific
domains of QoL scores are influenced by clinical vari-
ables, type of treatment, and patient population in differ-
ent ways and to a different extent14,15. However, data on
QoL during and after specific treatment modalities, and
associations of QoL with clinical features, are limited,
but are considered crucial for using QoL scores in multi-
modal setting.
In this study we aim to evaluate QoL in three differ-
ent groups of patients treated for breast cancer at the
Oncology Department of University Hospital Center –
those receiving adjuvant chemotherapy (AC), those re-
ceiving adjuvant radiotherapy (AR), and long term survi-
vors (LTS).
Patients and Methods
Study design
Cross-sectional descriptive study.
Patients and settings
The sample consisted of 60 postmenopausal women
with diagnosed, histologically confirmed UICC stage
I–IIIa operated breast cancer. Other inclusion criteria
were: ability to give consent, to read and speak Croatian,
and to understand the purpose of the study. Those who
had difficulty in understanding the questionnaire or
communicating in Croatian, or had known history of psy-
chiatric disorder or dementia were excluded from study.
Three groups of 20 patients each were enrolled: pa-
tients receiving adjuvant chemotherapy following pri-
mary surgery (AC), patients receiving adjuvant radio-
therapy following primary surgery (AR), and patients
who are considered long term survivors who were with-
out local, regional or distant relapse at least 5 years after
completion of their surgery and adjuvant treatment
(LTS). Eight patients in the AR radiotherapy group re-
ceived previous adjuvant chemotherapy.
Chemotherapy was given according to our local treat-
ment policy, in concordance with St. Gallen consensus16.
Majority of patients received FEC (N=17), consisting of
fluorouracil 600 mg/m2 iv, epirubicin 75 mg/m2 iv, and
cyclofosfamide 600 mg/m2 iv every three weeks for 6 cy-
cles. The remaining patients (N=3) received CMF, con-
sisting of cyclofosfamide 600 mg/m2 iv, methotrexate 40
mg/m2 iv, 5-fluorouracil 600 mg/m2 iv every three weeks
for 6 cycles.
Radiotherapy involved whole breast irradiation for all
BCS patients (N=12) or chest wall irradiation after mas-
tectomy (N=8) if tumor size was more than 5 cm or if
three or more lymph nodes were involved. Regional no-
dal coverage was added if more than three lymph nodes
were involved, irrespective of the type of breast surgery.
The prescribed dose for all patients was 2.25 Gy per daily
fraction, 5 days per week for 4 weeks, with total dose of
45 Gy, followed by a tumor bed boost of 10 Gy in 4 frac-
tions for BCS patients.
All patients were recruited as outpatients within On-
cology Department of University Hospital in period
2007–2008.
Instruments
QoL was assessed using the Croatian version of the
European Organization for Research and Treatment of
Cancer (EORTC) QLQ-C30 core questionnaire (version
3) with the breast module (EORTC QLQ-BR23) after
copyright was obtained17,18. The QLQ-C30 is a validated,
self-reported measure of core quality of life items cover-
ing physical, personal, role, cognitive, emotional and so-
cial domains, as well as global health status. The QLQ-
C30 is a 30-item survey with scores ranging from 0 (not
at all) to 4 (very much). Patient responses were combined
and computed to a 0 to 100 scale according to scoring
manual provided by the EORTC19. Completion of ques-
tionnaire requires an average 11–12 minutes. The C30
questionnaire was found to be reliable and valid in multi-
cultural setting20.
The QLQ-BR23 is a tumor specific tool consisting of
23 items pertaining to body image, sexuality, future per-
spective and side-effects related to different treatment
modalities such as surgery, chemotherapy or radiother-
apy. Each item is rated on a scale from 0 (not at all) to 4
(very much). With respect to functional scales, higher
scores represent higher levels of functioning, while higher
symptoms oriented scale score correspond to higher lev-
els of symptoms. The Croatian version of instrument was
tested for its validity and reliability. For both the QLQ-
-C30 and QLQ-BR23, higher functional scale scores rep-
resent higher levels of function, while for the symptom
oriented scales higher scores represent higher levels of
symptoms.
All patients who were offered to enter in study have
accepted and successfully fulfilled questionnaires after
written informed consent was obtained.
Statistical analysis
c²-test or Fisher’s exact test were used to compare
nominal categorical variables between groups and Krus-
kal-Wallis test was used to compare ordinal categorical
variables and numerical variables between groups. p val-
ues <0.05 were considered significant. Effects of clinical
and demographic factors on different quality of life scales
were tested using multiple regression analysis with a
stepwise selection of significant variables. The following
variables were included in multiple regression analysis:
age (numerical variable), type of surgery (mastectomy vs.
breast conserving surgery), tumor diameter (numerical
variable), estrogen receptor status (positive vs. negative),
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and axillary involvement (positive vs. negative). For mul-
tiple regression analysis p values <0.01 were considered
significant to account for multiple comparisons. All sta-
tistical analysis was performed using MedCalc (v11.5.1,
MedCalc Software, Mariakerke, Belgium).
Procedure
Data were collected from 2007 to 2008. The study was
approved by the institutional ethical committee. Rele-
vant clinical data were obtained from review of patients
records. Patients receiving adjuvant chemotherapy were
assessed during midway through their chemotherapy
course, while patients receiving adjuvant radiotherapy
were assessed after the third week of radiotherapy (after
the middle of radiotherapy course). Breast cancer survi-
vors were assessed on their regular annual outpatient
check-up visits. Data were collected by the attending
oncologist and study nurse.
Results
Patient’s characteristics are presented in Table 1. The
majority of tumors were T2 (2–5 cm), with ductal histol-
ogy. Most patients in the AR and LTS groups had grade 2
and ER positive cancers. HER2 status was available only
in AR and AC groups. No statistically significant differ-
ence was found between groups with respect to histology,
grade, ER status, HER2 status, or tumor diameter. Re-
garding axillary involvement, 50% patients in AR group
had N0 disease, while in AC and LTS groups 35% and
55% patients had N0 disease, respectively, although this
difference was not statistically significant. Women in the
LTS group were more likely to have undergone radical
surgery (p=0.007, c²-test), owing to different practice
patterns at the time of their treatment. Patients in AC
group were younger than patients in other two groups
(p=0.048, Kruskal-Wallis test).
Distribution of scores of QoL scales in QLQ-C30 v 3.0
core questionnaire are presented in Table 2 and Figure 1.
There were no statistically significant differences in QoL
as measured by the QLQ-C30. According to mean distri-
bution, cognitive functioning, social functioning and
physical functioning were the least affected QoL scales in
all three patients groups, while insomnia and pain were
the most affected. Women in the AC group had the high-
est global health status QoL score, and also tended to
have higher functional scale scores than women in the
AR or LTS groups but these differences were not statisti-
cally significant.
In QLQ BR23 questionnaire analysis, body image was
the most affected scale in all three patients groups, while
sexual functioning was minimally affected (Table 3, Fig-
ure 2). There was no statistically significant difference
between groups (Table 3).
Multiple regression analysis was undertaken to deter-
mine associations between QoL scales and clinical fac-
tors. Age was the only statistically significant predictor
for the global health status scale (adjusted R2=0.18, b=
–1.11, standard error (b=0.3, p=0.0005) and for the con-
stipation scale (adjusted R2=0.11, b=0.81, standard error
(b)=0.29, p=0.006). For other QoL scales, no statistically
significant predictors were found by multiple regression
analysis.
Discussion and Conclusion
This study is first to evaluate impact of adjuvant
treatment on QoL in breast cancer patients in Croatia,
and to compare it with QoL in breast cancer survivors.
This study is a preliminary report to assess patient re-
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TABLE 1
PATIENT CLINICAL AND TREATMENT CHARACTERISTICS
Variable
Participants (N=60)
pAR
(N=20)
AC
(N=20)
LTS
(N=20)
Age /years/ 0.048*
Mean (standard
deviation)
66 (10.1) 58.6 (10.5) 65.1 (8.8)
Median (range) 68.5 (47–78) 58 (47–79) 64 (47–82)
Surgery 0.007**
Mastectomy /N/ 8 9 17
BCS /N/ 12 11 3
Tumor diameter 0.416*
<2 cm /N/ 8 7 3
2–5 cm /N/ 11 11 17
>5 cm /N/ 1 2 0
Histology 0.907**
DIC /N/ 16 17 18
LIC /N/ 2 2 1
Other /N/ 2 1 1
Tumor grade 0.087*
Grade 1 /N/ 1 2 2
Grade 2 /N/ 16 9 16
Grade 3 /N/ 3 9 2
Estrogen receptor 0.092**
Positive /N/ 18 12 14
Negative /N/ 2 8 6
HER2 b 0.158***
Positive /N/ 2 5 N/A
Negative /N/ 18 15 N/A
Axillary lymph node metastases 0.419**
Not present /N/ 10 7 11
Present /N/ 10 13 9
* Kruskal-Wallis test, ** ÷²-test, *** Fisher’s exact test, AR – pa-
tients receiving adjuvant radiotherapy, AC – patients receiving
adjuvant chemotherapy, LTS – patients who are considered as
breast cancer survivors, BCS – breast conserving surgery, DIC –
ductal invasive carcinoma, LIC – lobular invasive carcinoma
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sponses to a quality of life survey, extract initial data re-
garding patient observed QoL (as most important pa-
tient-reported outcome), and evaluate the influence of
basic clinical parameters on QoL scales.
Each of aforesaid three dominant breast cancer pa-
tient groups has its specific QoL and treatment-related
issues that complicate their comparison but from several
reports is notable fact that during adjuvant treatment
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TABLE 2
DISTRIBUTION OF FUNCTION AND SYMPTOM SCORES IN DIFFERENT GROUPS OF WOMEN WITH BREAST CANCER MEASURED
BY EORTC QLQ-C30
Variables
Participants (N=60) p (Kruskal-
-Wallis test)AR (N=20) AC (N=20) LTS (N=20)
Global health status /median (IQR)/ 50 (33.4) 54.2 (29.2) 50 (33.4) 0.247
Physical functioning /median (IQR)/ 80 (29.9) 86.7 (20) 80 (33.3) 0.078
Role functioning /median (IQR)/ 83.3 (41.7) 83.3 (33.3) 91.7 (33.3) 0.970
Emotional functioning /median (IQR)/ 75 (50) 66.7 (16.7) 70.9 (29.2) 0.913
Cognitive functioning /median (IQR)/ 83.3 (33.3) 100 (16.7) 83.3 (33.3) 0.066
Social functioning /median (IQR)/ 83.3 (33.3) 100 (25) 100 (25) 0.385
Fatigue /median (IQR)/ 33.3 (50.1) 22.2 (22.2) 22.2 (22.2) 0.768
Nausea and vomiting /median (IQR)/ 0 (16.7) 16.7 (33.3) 0 (16.7) 0.062
Pain /median (IQR)/ 16.7 (50) 25 (33.3) 33.3 (33.3) 0.756
Dyspnoea /median (IQR)/ 0 (33.3) 0 (16.7) 0 (33.3) 0.361
Insomnia /median (IQR)/ 33.3 (66.7) 33.3 (50) 33.3 (33.3) 0.681
Appetite loss /median (IQR)/ 0 (33.3) 0 (33.3) 0 (0) 0.574
Constipation /median (IQR)/ 0 (33.3) 0 (0) 0 (16.7) 0.328
Diarrhoea /median (IQR)/ 0 (0) 0 (0) 0 (0) 0.868
Financial difficulties /median (IQR)/ 0 (66.7) 16.7 (33.3) 0 (0) 0.140
AR – patients receiving adjuvant radiotherapy, AC – patients receiving adjuvant chemotherapy, LTS – patients who are considered as
breast cancer survivors, IQR – interquartile range
Fig. 1. Quality of life according to EORTC quality of life QLQ-
-C30 questionnaire – comparison of mean scores by three groups
of patients. Scales: GHS- global health status, PF – physical
functioning, RF – role functioning, EF – emotional functioning,
CF – cognitive functioning, SF – social functioning, F – fatigue,
NV – nausea and vomiting, P – pain, D – dyspnea, I – insomnia,
AL – appetite loss, C – constipation, DI – diarrhea, FD – finan-
cial difficulties.
Fig. 2. Quality of life according to EORTC quality of life QLQ
BR23 questionnaire – comparison of mean scores by three groups
of patients. Scales: BI – body image, SF – sexual functioning, SE
– sexual enjoyment, FP – future perspectives, STSE – systemic
therapy side effects, BS – breast symptoms, AS – arm symptoms,
UHL – upset by hair loss.
U:\coll-antropolo\coll-antro-4-2012\12083 Murgic.vp
21. prosinac 2012 9:19:33
Color profile: Disabled
Composite  150 lpi at 45 degrees
QoL is decreasing with recovery on pretreatment levels
up to six months upon completing treatment21–26.
Breast cancer survivors have QoL mainly comparable
to the responding women with no history of cancer, but
in certain QoL domains there might exist considerable
and durable impairment9,27,28. For instance, impaired
QoL was noted in areas such as arm problems and
sexuality29.
As women in AR and AC groups had undergone their
surgeries within 10 months of study entrance, their re-
cent cancer diagnosis and breast surgery could poten-
tially influence their QoL during adjuvant therapy30.
The three major QoL domains in QLQ-C30 v 3.0 ques-
tionnaire, consisting of global health status/QoL, five
functional scales and nine symptom scales, do not have
the same clinical significance and relevance. In the larg-
est meta-analysis on QoL data within more than ten
thousand patients included in EORTC clinical trials, only
three out of fifteen scales- physical functioning, pain and
appetite loss, proved to be of survival significance31.
With the introduction of BCS plus irradiation, more
patients were offered less aggressive treatment with
equal oncological outcomes, but with a more beneficial
QoL profile32. Reviewing the body of literature, there is
much disagreement regarding the impact of primary sur-
gical treatment on long-term QoL in breast cancer pa-
tients, with no study clearly demonstrating significant
differences in the majority of QoL domains between pa-
tients treated with mastectomy or breast conserving
surgery33–35.
The relationship between the type of surgery and QoL
is controversial. Some studies reported that patients un-
dergoing breast conserving surgery had a better body
image36,37 while others observed better psychological ad-
justment in women who had mastectomy despite the
similar QoL profile38. In work done by Janni et al. was
found that women undergoing mastectomy were less sat-
isfied with cosmetic results, reporting higher emotional
stress caused by their physical appearance. Regret about
the surgical treatment chosen and impairment of daily
life caused by primary treatment were similar among the
groups, however39. On the other hand, there are reports
about worse physical functioning in women undergoing
breast conserving surgery compared to those undergoing
mastectomy36.
Many women receiving adjuvant radiotherapy repor-
ted problems with body image, particularly those who
had undergone mastectomy40,41. We did not find a signifi-
cant difference in overall QoL scores between women
who had mastectomy compared to those who had breast
conserving surgery.
The fact that some scales of QoL in the LTS group are
affected more than in other two groups (global health
status and body image) suggest that some other factors
also might influence QoL in breast cancer survivors,
such as fear of recurrence and problems associated with
aging42.
Data on direct comparison of QoL in women undergo-
ing adjuvant chemotherapy or radiotherapy is scarce.
One report described how predefined domains of QoL
among postmenopausal women change over time, but
failed to include scale scores comparisons. The women
receiving adjuvant chemotherapy showed a significant
decrease in the overall QoL, physical, role, social, and
cognitive functioning and body image and anxiety be-
tween baseline and the completion of six cycles of chemo-
therapy, while fatigue, nausea/vomiting, dyspnoea, appe-
tite loss, constipation, pain, systemic therapy side effects,
hair loss and depression increased significantly during
the same period. On the other hand, among women re-
ceiving radiotherapy, a significant decrease was observed
for the overall QoL, role and physical functioning, body
image and anxiety between baseline and two weeks after
completion of the treatment. Significant increases were
seen in fatigue and dyspnoea, nausea/vomiting, pain, fi-
nancial difficulties, constipation, systemic therapy side
effects, arm and breast symptoms during the same time
frame26.
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TABLE 3
DISTRIBUTION OF FUNCTION AND SYMPTOM SCORES IN DIFFERENT GROUPS OF WOMEN WITH BREAST CANCER MEASURED
BY EORTC BR23 BREAST CANCER MODULE
Variables
Participants (N=60) p (Kruskal-
-Wallis test)AR (N=20) AC (N=20) LTS (N=20)
Body image /median (IQR)/ 83.4 (37.5) 91.7 (33.3) 87.5 (29.2) 0.863
Sexual functioning /median (IQR)/ 0 (8.4) 0 (25) 0 (25) 0.825
Sexual enjoyment /median (IQR)/ 33.3 (16.7) 33.3 (50) 66.7 (66.7) 0.460
Future perspective /median (IQR)/ 33.3 (50) 33.3 (33.3) 66.7 (50) 0.118
Systemic therapy side effects /median (IQR)/ 19.1 (28.6) 26.2 (14.3) 14.3 (27.5) 0.379
Breast symptoms /median (IQR)/ 16.7 (16.7) 16.7 (12.5) 8.3 (29.15) 0.169
Arm symptoms /median (IQR)/ 16.7 (32.9) 22.2 (16.7) 11.1 (33.3) 0.426
Upset by hair loss /median (IQR)/ 50 (100) 33.3 (66.7) 33.3 (8.3) 0.814
AR – patients receiving adjuvant radiotherapy, AC – patients receiving adjuvant chemotherapy, LTS – patients who are considered as
breast cancer survivors, IQR – interquartile range
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Onmultivariate analysis we found significant correla-
tion between age and global health status scale and con-
stipation scale. Age is considered as important predictor
of QoL, and global health status likely represent sub-
ject’s general QoL. It is expected that with greater num-
ber of patients we would yield some other significant cor-
relation between clinical variables and QoL domains.
The purpose of this study is to give insight over QoL
domains and influence of clinical variables on QoL in
three groups of breast cancer patients most commonly
seen in clinical practice. This is the first study conducted
in Croatia aiming to evaluate the association between
clinical factors and QoL in different groups of women
with breast cancer.
We found no statistically significant differences in
QoL between patients undergoing adjuvant treatment
and the long-term breast cancer survivors in this small
pilot exploratory study. This study is hypothesis generat-
ing in that some QoL domains may improve and some
may not or even worsen during survivorship period. It is
worthwhile to alert follow-up care providers of the QoL
domains that are impaired in LTS and particularly of do-
mains impacted to a similar degree as during adjuvant
therapy. Future studies to build upon this work are nec-
essary to best guide survivorship care in the growing
Croatian breast cancer patient population. In the era of
targeted treatment, we should identified subjects with
impaired QoL, and to target our attention and care to
those affected QoL domains.
The limitations of this study include its cross-sec-
tional design and limited study population, although pa-
tient number was sufficient to acquire initial QoL obser-
vation. Furthermore, QoL is assessed at one point in
time. The trend of QoL and its specific scales, and treat-
ment-related symptoms over time were not evaluated.
In future research, QoL should be assessed with pro-
spective collection of baseline data in order to better
delinate associations between QoL and cancer treat-
ment. In addition, larger prospective studies are required
to follow the dynamics of QoL scales both in the adjuvant
setting and in breast cancer survivors, in order to acquire
more detailed information about symptoms and the can-
cer treatment burden experienced by different groups of
patients.
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KVALITETA @IVOTA U BOLESNICA S RAKOM DOJKE KOJE PRIMAJU ADJUVANTNU TERAPIJU
– USPOREDBA S BOLESNICAMA KOJE SU DUGOTRAJNO PRE@IVJELE RAK DOJKE
S A @ E T A K
Kvaliteta `ivota (K@) je va`an detalj u procesu odlu~ivanju o na~inu lije~enja raka dojke. Podaci o usporedbi K@
nakon razli~itih oblika adjuvantnog lije~enja i podataka o K@ u bolesnica koje su dugotrajno pre`ivjele rak dojke su
skromni. Cilj ovog istra`ivanja bio je usporediti kvantitativne vrijednosti domena K@ bolesnica koji su primale adju-
vantno lije~enje i bolesnica koje su dugotrajno pre`ivjele rak dojke (koje su u pra}enju) te povezati pojedine domene K@
sa klini~kim podacima. [ezdeset bolesnica je bilo uklju~eno u studiju: 20 za vrijeme adjuvantne radioterapije, 20 za
vrijeme adjuvantne kemoterapije i 20 bolesnica koje su dugotrajno pre`ivjele rak dojke. K@ je procijenjena primjenom
osnovnog EORTC upitnika QLQ-C30 i specifi~nog modula za rak dojke QLQ-BR23. Bodovne vrijednosti K@ uspore|ene
su izme|u skupina Kruskal-Wallis testom, a utjecaj klini~kih ~imbenika na razli~ite domene K@ testiran je multiplom
regresijskom analizom. Nisu na|ene razlike izme|u tri skupine niti u jednoj od skala K@. Mjereno QLQ-C30 upitnikom,
najmanje pogo|ene skale K@ su bile kognitivno funkcioniranje, socijalno funkcioniranje i tjelesno funkcioniranje u sve
tri skupine boesnica, dok su skale nesanice i bola bile najizra`enije negativno pogo|ene. Me|u skupinama, najvi{e
bodovne vrijednosti op}eg zdravstvenog statusa i drugih funkcijskih skala bile su u skupini bolesnica koje su primale
adjuvantnu kemoterapiju. Mjereno QLQ-BR23 upitnikom, skala predod`be tijela bila je najvi{e pogo|ena dok je skala
seksualnog funkcioniranja bila najmanje pogo|ena u sve tri skupine. Multipla regresijska analiza pokazala je da je dob
bolesnica jedini statisti~ki zna~ajan prediktor za skalu op}eg zdravstvenog statusa i skalu konstipacije. Na{i rezultati
su pokazali sli~nu i povoljnu K@ u sve tri skupine bolesnica te su pru`ili osnovne informacije o K@ u hrvatskih bolesnica
s rakom dojke.
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